Mortality rates are considerably higher in chronic ischemic heart disease (IHD) patients with non-insulin-dependent diabetes mellitus (NIDDM) than in those who are nondiabetics. The relationship between different types of antihyperglycemic pharmacological therapy and mortality rate in this NIDDM population is uncertain. We aimed to examine the survival in NIDDM patients with IHD using various types of oral antidiabetic treatments over a 5-year follow-up period. The study sample comprised 11,440 patients with a previous myocardial infarction and/or stable anginal syndrome, aged 45–74 years, who were screened, but not included in the Bezafibrate Infarction Prevention study. Among them, 9,045 were nondiabetics and 2,395 diabetics. The diabetic patients were divided into four groups on the basis of their therapeutic regimen at screening: diet alone (n = 990), sulfonylureas (n = 1,041), metformin (n = 78) and a combination of a sulfonylurea and metformin (n = 266). All NIDDM groups were similar with regard to age, gender, hypertension, smoking, heart failure, angina and prior myocardial infarction. Crude mortality rate was lower in the nondiabetic group (11.21 vs. 21.8%; p < 0.001). In the diabetic group, mortality was 18.5% for patients on diet alone, 22.5% for those on sulfonylureas, 25.6% for patients on metformin, and 31.6% for the combined sulfonylurea/metformin group (p < 0.01). When analyzing age-adjusted mortality rate and actuarial survival curves, the lowest mortality was found in patients on diet alone and the highest in patients on metformin (alone or in combination with sulfonylureas). After adjustment for variables connected with long-term prognosis, the use of metformin was associated with increased relative risk (RR) for all-cause mortality of 1.42 (95% CI 1.10–1.85), whereas the use of sulfonylureas alone was not [RR 1.11 (95% CI 0.90–1.36)]. NIDDM patients with IHD using metformin, alone or in combination with sulfonylureas, exhibited a significantly increased mortality. Until the results of problem-oriented prospective studies on oral control of NIDDM will be available, alternative therapeutic approaches should be investigated in these patients.

Keywords:
Coronary disease, Diabetes mellitus, Metformin, Mortality, Sulfonylureas
1.
Bornstein NM: Epidemiology of stroke; in Daniel WG, Kronzon I, Mugge A (eds): Cardiogenic Embolism. Baltimore, Williams & Wilkins, 1996, pp 1–6.
2.
Kessler I: Mortality experience in diabetic patients. Am J Med 1971;51:715–724.
3.
Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: An epidemiological view. Diabetes Metab Rev 1987;3:463–524.
4.
Robertson W, Strong J: Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest 1968;18:538–551.
5.
Hamby R, Sherman L, Mehta J, Aintablian A: Reappraisal of the role of the diabetic state in coronary artery disease. Chest 1976;70:251–257.
6.
Turner RC, Holman RR: The UK prospective diabetes study. Ann Med 1996;28:439–444.
7.
Klimt CR, Knatterud GL, Meinert CL, Prout TE: The University Group Diabetes Program; a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline characteristics. II. Mortality results. Diabetes 1970;19(suppl 2):747–830.
8.
Innerfield RJ: Metformin-associated mortality in US studies. N Engl J Med 1996;334:1611–1613.
9.
American Diabetes Association Consensus Statement: The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996;19:S54–S61.
10.
Goldbourt U, Behar S, Reicher-Reiss H, et al: Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993;71:909–915.
11.
Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U: Fibrinogen is a predictor of mortality in coronary artery disease patients. Arterioscler Thromb Vasc Biol 1996;16:351–356.
12.
International Classification of Diseases: Clinical Modification, 9th revision. Ann Arbor, Edwards, 1981, vol 1.
13.
SAS Institute: SAS/STAT. User’s Guide, version 6, ed 4. Cary, SAS Institute, 1987, vol 2.
14.
Yaari S, Goldbourt U: A SAS program for evaluating person-years of risk in cohort studies. Comput Biol Med 1989;19:353–359.
15.
SAS/STAT software: Changes and Enhancements, release 6.07. SAS technical report P-229. Cary, SAS Institute, 1992, p 620.
16.
Goldner MG, Knatterud GL, Prout TE: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. III. Clinical implication of UGDP results. JAMA 1971;218:1400–1410.
17.
DeFronzo RA, Barzilai R, Simonson DC: Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294–1301.
18.
Grant PJ: The effects of high and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996;19:64–66.
19.
Carlsen SM, Rossvoll O, Bjerve KS, Folling I: Metformin improves lipid pattern in nondiabetic patients with coronary heart disease. J Intern Med 1996;239:227–233.
20.
DeFronzo RA, Goodman AM, Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541–549.
21.
Adams JF, Clark JS, Ireland JT, Kesson CM, Watson WS: Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy. Diabetologia 1983;24:16–18.
22.
Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517–527.
23.
Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230–236.
24.
Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM: Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862–867.
25.
Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265–266.
26.
Marchetti P, Navalesi R: Pharmacokinetic-pharmacodynamic relationships of oral hypoglycemic agents: An update. Clin Pharmacokinet 1989;16:100–128.
27.
Smits P, Thien T: Cardiovascular effects of sulphonylurea derivatives. Implication for the treatment of NIDDM? Diabetologia 1995;38:116–121.
28.
Brady PA, Terzic A: The sulfonylurea controversy: More questions from the heart. J Am Coll Cardiol 1998;31:950–956.
29.
Duncker DJ, van Zon NS, Altman JD, Pavek DJ, Bache RJ: Role of K+ ATP channels in coronary vasodilation during exercise. Circulation 1993;88:1245–1253.
30.
Cole WC, McPherson CD, Sontag D: ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571–581.
31.
Grover GJ, Sleph PG, Dzwonick BS: Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interactions with adenosine A1-receptors. Circulation 1992;86:1310–1316.
32.
Klimt CR, Canner PL, Jacobs DR, Tominaga S: The prognostic importance of plasma glucose levels and of the use of oral hypoglycemic drugs after myocardial infarction in men. Diabetes 1977;26:453–465.
33.
Herman LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A: Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations. Diabetes Care 1994;17:1100–1109.
34.
UK Prospective Diabetes Study Group. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998;21:87–92.
35.
UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
36.
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865.
37.
Nathan DM: Some answers, more controversy, from UKPDS. Lancet 1998;352:832–833.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.